FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282920278> ?p ?o ?g. }

• W4282920278 endingPage "5611" @default.
• W4282920278 startingPage "5611" @default.
• W4282920278 abstract "Abstract TGFβ is a secreted protein produced by tumors that promotes cancer progression primarily via the suppression of both the innate and adaptive immune systems. This makes TGFβ a promising immunotherapeutic target in cancer. It is ubiquitously expressed in a latent (L-TGFβ) form and the latent form has been shown to promote an immune suppressive phenotype within the tumor microenvironment. Integrin αvβ8 specifically binds to L-TGFβ. This interaction is essential for the activation of L-TGFβ-mediated signals in a variety of immune cell types. Interestingly, it has been recently shown that integrin αvβ8-mediated TGFβ activation can active directly through L-TGFβ and does not require the release of active TGFβ (1). Inhibition of integrin αvβ8-mediated TGFβ activation has been shown to block immunosuppressive regulatory T cell differentiation and enhance the recruitment of cytotoxic T cells into the tumor microenvironment (2). Here, we demonstrate by Surface Plasmon Resonance (SPR) that CRB-601, our selective inhibitor of integrin αvβ8 monoclonal antibody candidate, has a high affinity and specificity for the integrin αvβ8 complex. Moreover, in comparison to competitor molecules, such as ADWA-11, CRB-601 substantially blocks TGFβ activation in a reporter cell assay system. Additionally, using syngeneic mouse models, we evaluated the anti-tumoral properties of CRB-601 as a monotherapy, as well as in combination with immune checkpoints therapies. Findings from this study highlight the importance of integrin αvβ8 blockade in mediating the immune landscape within the tumor and leads to an enhanced response to immune checkpoint therapy. In conclusion, CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that enhances the activity of immune checkpoint inhibitors in vivo and holds promise as a potential combination partner for immunotherapy. Investigational New Drug (IND) enabling studies are currently underway. References: 1: Campbell MG. et al. (2020) Cyro-EM reveals integrin-mediated TGF-β activation without release from latent TGF-β. Cell 180, 490-501. 2: Mariathasan S. et al. (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544-48. Citation Format: Andrew Kolodziej, Eric Haines, Richard Morse, Eugene Zhukovsky. CRB-601: A highly potent and selective integrin αvβ8 blocking antibody with anti-tumoral properties [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5611." @default.
• W4282920278 created "2022-06-16" @default.
• W4282920278 creator A5000490773 @default.
• W4282920278 creator A5010328110 @default.
• W4282920278 creator A5067216355 @default.
• W4282920278 creator A5084193892 @default.
• W4282920278 date "2022-06-15" @default.
• W4282920278 modified "2023-10-07" @default.
• W4282920278 title "Abstract 5611: CRB-601: A highly potent and selective integrin αvβ8 blocking antibody with anti-tumoral properties" @default.
• W4282920278 doi "https://doi.org/10.1158/1538-7445.am2022-5611" @default.
• W4282920278 hasPublicationYear "2022" @default.
• W4282920278 type Work @default.
• W4282920278 citedByCount "0" @default.
• W4282920278 crossrefType "journal-article" @default.
• W4282920278 hasAuthorship W4282920278A5000490773 @default.
• W4282920278 hasAuthorship W4282920278A5010328110 @default.
• W4282920278 hasAuthorship W4282920278A5067216355 @default.
• W4282920278 hasAuthorship W4282920278A5084193892 @default.
• W4282920278 hasConcept C154317977 @default.
• W4282920278 hasConcept C159654299 @default.
• W4282920278 hasConcept C170493617 @default.
• W4282920278 hasConcept C185592680 @default.
• W4282920278 hasConcept C195687474 @default.
• W4282920278 hasConcept C202751555 @default.
• W4282920278 hasConcept C203014093 @default.
• W4282920278 hasConcept C2776090121 @default.
• W4282920278 hasConcept C2776107976 @default.
• W4282920278 hasConcept C502942594 @default.
• W4282920278 hasConcept C55493867 @default.
• W4282920278 hasConcept C86803240 @default.
• W4282920278 hasConcept C8891405 @default.
• W4282920278 hasConcept C95444343 @default.
• W4282920278 hasConceptScore W4282920278C154317977 @default.
• W4282920278 hasConceptScore W4282920278C159654299 @default.
• W4282920278 hasConceptScore W4282920278C170493617 @default.
• W4282920278 hasConceptScore W4282920278C185592680 @default.
• W4282920278 hasConceptScore W4282920278C195687474 @default.
• W4282920278 hasConceptScore W4282920278C202751555 @default.
• W4282920278 hasConceptScore W4282920278C203014093 @default.
• W4282920278 hasConceptScore W4282920278C2776090121 @default.
• W4282920278 hasConceptScore W4282920278C2776107976 @default.
• W4282920278 hasConceptScore W4282920278C502942594 @default.
• W4282920278 hasConceptScore W4282920278C55493867 @default.
• W4282920278 hasConceptScore W4282920278C86803240 @default.
• W4282920278 hasConceptScore W4282920278C8891405 @default.
• W4282920278 hasConceptScore W4282920278C95444343 @default.
• W4282920278 hasIssue "12_Supplement" @default.
• W4282920278 hasLocation W42829202781 @default.
• W4282920278 hasOpenAccess W4282920278 @default.
• W4282920278 hasPrimaryLocation W42829202781 @default.
• W4282920278 hasRelatedWork W1497833379 @default.
• W4282920278 hasRelatedWork W1964266791 @default.
• W4282920278 hasRelatedWork W2004466917 @default.
• W4282920278 hasRelatedWork W2040631670 @default.
• W4282920278 hasRelatedWork W2049624095 @default.
• W4282920278 hasRelatedWork W2110968275 @default.
• W4282920278 hasRelatedWork W2414729062 @default.
• W4282920278 hasRelatedWork W3087470930 @default.
• W4282920278 hasRelatedWork W4313313459 @default.
• W4282920278 hasRelatedWork W4317738354 @default.
• W4282920278 hasVolume "82" @default.
• W4282920278 isParatext "false" @default.
• W4282920278 isRetracted "false" @default.
• W4282920278 workType "article" @default.